MedTrace Logo

Dapagliflozin Effect on Rheumatic Mitral Stenosis

NCT05618223 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2022-11-21

No results posted yet for this study

Summary

Rheumatic mitral stenosis remains a health problem in developing countries. Progressive fibrosis of the valves and myocardium is the main pathophysiology that plays an important role. Dapagliflozin has various beneficial effects on the heart by reducing fibrosis, reducing inflammation, and improving patient quality of life. However, the role of this therapy is unknown in patients with rheumatic mitral stenosis.

Conditions

Interventions

DRUG

Dapagliflozin

Dapagliflozin 10 mg once daily in addition to standard therapy

Sponsors & Collaborators

  • Universitas Sebelas Maret

    lead OTHER

Principal Investigators

  • An Aldia Asrial, MD · Universitas Sebelas Maret

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-01
Primary Completion
2023-05-31
Completion
2023-06-30

Countries

  • Indonesia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05618223 on ClinicalTrials.gov